Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/vativorx_714/public/wp-includes/functions.php on line 6121
What does a PBM do? Use this handy guide to explain - VativoRx

Call Us: 888-488-5750

What does a PBM do? Use this handy guide to explain

We recently saw a well-done explanation of how PBMs interact with the patient’s journey and wanted to share it with our readers.

The short article was created by Pharmaceutical Care Management Association (PCMA), the industry’s representative organization in Washington.

While most of us are deeply familiar with that journey, it’s easy to forget that, to healthcare consumers, that process may not be as clear as it could be.

In the article, the reader is walked through six discreet stages, from doctor’s visit through medicine dispensing and beyond. 

If you regularly come in contact with patients, some of whom may be struggling with who’s who in their healthcare process, you might want to bookmark this short article about what PBMs do for patients for sharing.

And for a deeper dive into how PBMs can do better, check out these articles from VativoRx:

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »